Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

July 26-27, 2010: Blood Products Advisory Committee Meeting- XMRV - INFO ON THIS????

Discussion in 'Action Alerts and Advocacy' started by muffin, Jul 26, 2010.

  1. muffin

    muffin Senior Member

    Messages:
    940
    Likes:
    10
    Does anyone know if this is open to the public? Is anyone going? Will the FDA put this meeting out on the Internet via a video feed or transcript? Any info on this meeting would be appreciated.

    FYI Info below (Sorry if it is elsewhere):
    July 26-27, 2010: Blood Products Advisory Committee Meeting - Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Informational Presentation
    BLOOD PRODUCTS ADVISORY COMMITTEE MEETING
    98 th Meeting, July 26-27, 2010
    Hilton Washington D.C./North
    620 Perry Parkway, Gaithersburg, MD
    Topic: Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Informational Presentation
    Issue: FDA is updating the committee on XMRV, the newly identified human retrovirus (a gammaretrovirus), and FDAs collaborative efforts with other public health agencies and blood establishments to determine whether XMRV poses a safety concern for the blood supply.
    Background:
    Xenotropic Murine Leukemia Virus-Related Virus (XMRV) is a newly identified retrovirus and the first gammaretrovirus of the Retroviridae family detected in humans. It is unrelated to HIV but highly similar to mouse retroviruses. Gammaretroviruses are widespread in vertebrates, but do not establish infection readily in immunocompetent hosts. Gammaretroviruses in animals are implicated in a wide range of diseases including cancers, immunodeficiency, and neurological disorders. XMRV is a simple retrovirus with gag, pol and env genes and unlike HIV or HTLV, has no accessory or regulatory genes. The genome is a dimer of linear, positive-sense, single stranded RNA about 8,300 nucleotides long.
    XMRV was identified using a viral detection DNA microarray composed of oligonucleotides corresponding to the most conserved sequences of all known viruses (1). Using this array, gammaretroviral sequences were identified in samples from 7/11 prostate cancer (PC) patients that were homozygous (QQ) for the R462 mutation for RNAse L which is an important molecule in the innate antiviral response (2). A survey of an additional 86 PC tumors by RT-PCR specific for XMRV showed that 40% of QQ cases were positive for XMRV compared with 1.5% of heterozygous RQ and homozygous wild type RR cases. Subsequently an analysis of 334 consecutive prostate resection specimens using a quantitative PCR assay and immunohistochemistry showed that 6% were positive for XMRV DNA and 23% for protein expression. Taken together, these findings suggest an association of XMRV with prostate cancer (3).
    A subsequent study showed that XMRV could also be detected in patients with Chronic Fatigue Syndrome (CFS), a disease of unknown etiology, known to affect several million people worldwide (4). DNA from peripheral blood mononuclear cells (PBMCs) of CFS patients and healthy controls was tested for the presence of XMRV sequences. XMRV sequences were found in 68 out of 101 CFS patients (67%), compared with 8 of 218 (3.7%) healthy US controls. The viral gene sequences identified in CFS patients clustered with sequences from PC and both sequences were virtually identical. Further investigation using activated CFS patient PBMC co-cultured with susceptible PC cells (LNCaP) showed that virus could be transmitted by cells and supernatant, as indicated by protein expression and transmission electron microscopy, suggesting that the virus being detected by protein expression was infectious. Virus could also be transmitted from 10/12 CFS patient plasma samples. Taken together, these studies suggested that both cell associated and cell-free transmission of XMRV is possible. Finally, antibodies to XMRV were detected in 9/18 CFS patients using a test based on the envelope of a closely related virus, spleen focus forming virus (SFFV).
    Preliminary data from a limited study of XMRV in an animal model (rhesus macaques) showed disseminated infection but only low but detectable transient viremia between 4-14 days. Seroconversion occurred at 11-14 days following inoculation, with titers peaking around day 95. Virus was isolated from T- and B- lymphocytes and NK cells in blood (but not macrophages), prostate epithelial cells, vaginal tissue, and there was evidence for viral replication in spleen, lung, lymph nodes and liver (5).
    Since the discovery of XMRV there have been several controversial reports about the association of XMRV with PC and CFS. Studies of an Irish PC cohort of 139 patients with the R462Q mutation showed no evidence of XMRV (6). In a German study, only 1/105 tissue samples were positive for XMRV DNA from non-familial PC while 1/70 samples were positive from men who did not have PC (7). In a different study of German PC patients, 589 PC tissues with the RNaseL R462Q mutation were tested using nested RT-PCR and all were found to be negative (8).
    In regard to CFS, several recent studies have reported negative findings of XMRV in blood. A Dutch study failed to detect XMRV in PBMC of patients with CFS (9) and similar findings were reported in two studies from the UK although a few samples showed XMRV neutralizing activity in one study (10,11). Studies conducted by CDC scientists in a US population of CFS cases and blood donors showed no evidence of XMRV infection in PBMC and plasma. These data do not lend support to an association of XMRV with CFS or its presence in blood donors. (13)
    Among other related findings are those recently reported by investigators in Germany that XMRV could be detected in respiratory secretions (14). In this study, 267 respiratory samples taken from German patients were screened for XMRV infection by PCR assay. The prevalence of XMRV DNA was 2.3% (3/75) in travelers from Asia who had respiratory tract infections; 3.2% (1/31) in patients with chronic obstructive pulmonary disease; 9.9% (16/161) in immunosuppressed patients with severe respiratory tract infections; 3.2% (2/62) in the healthy control group. It is not clear whether finding XMRV in the respiratory tract indicates that the virus can be transmitted by the respiratory route (14). In general, retroviruses, like HIV-1, are rarely transmitted through respiratory secretions.
    A compilation of all the XMRV studies done so far is shown in appendix I. The reasons for discrepancies between findings are not clear. Differences in cohorts, populations and test methods have been considered as potential causes. In addition, differences in geographic prevalence, genetic variation of the virus or other factors could also potentially contribute to these conflicting findings. Additional studies are needed to confirm disease association of XMRV and to fully understand the role of XMRV in disease causation.
    Discussion:
    (a) Detection methods:
    Currently there are no commercially approved/licensed tests for detection of XMRV infection. The assays used for research studies include PCR, EIA, Western blot, and immunohistochemical methods. The relative sensitivity and specificity of various assays have not been determined and standards for performance of assays have not yet been established.
    (b) Evaluation of Transfusion Risk in the US:
    Transmission through transfusion has not been shown, but is theoretically possible since virus has been detected in blood cells and there is evidence of cell-free virus. A seroprevalence study in Japan found 1.7% of random donors to be positive (12). Preliminary studies have shown that 3/2851 US blood donors (0.1%) were anti-XMRV antibody positive using a research immunoassay based on gag and env proteins (5).
    A Blood XMRV Scientific Research Working Group, led by the National Heart Lung and Blood Institute (NHLBI), has been established to identify and design research studies to evaluate whether XMRV poses a threat to blood safety. An evaluation of blood safety risks includes 1) an evaluation of the prevalence of XMRV in blood donors; 2) if prevalent in blood donors, a determination of whether the virus is transfusion-transmitted; and 3) if transfusion-transmitted, whether clinical manifestations occur. An evaluation of the prevalence of XMRV in blood donors necessitates a way to measure or identify the agent in blood specimens. The fact that different laboratories obtain different results for XMRV detection in patients specimens and different prevalence estimates in normal controls strongly suggests the need for the development of standard XMRV reference and clinical case and healthy donor prevalence panels for XMRV detection. Thus, development of XMRV nucleic acid test (NAT) analytical and clinical panels was identified as the first priority by the Working Group. As a first step towards this goal, an analytical reference panel was developed to validate NAT assays for use in donor survey studies . The panel was developed by the Blood Systems Research Institute which is the Central Laboratory for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Virus stocks were prepared from culture supernatants of the chronically infected prostate cancer cell line, 22Rv1. Following titration, reference infected cell preparations were established by spiking known numbers of infected cells into whole blood. Similarly, reference infected plasma preparations were established by spiking pedigreed-negative plasma with known viral titers of cell-free culture supernatants at serial dilutions. These coded analytical reference panels of specimens containing varying concentrations of XMRV virus as well as clinical panels which include biospecimens from blood donors, patients with Chronic Fatigue Syndrome whose blood was previously found to be positive for XMRV by the Whittemore Peterson Institute, and positive and negative control specimens are in the process of being tested by up to six participating laboratories to compare the sensitivity of their respective assays for XMRV. The study participants include laboratories from the NCI, FDA (two laboratories), CDC, Blood Systems Research Institute and the Whittemore Peterson Institute.

    Summary:
    The BPAC session will include several informational presentations on XMRV including a background and review of studies that led to the identification of the virus, ongoing validation studies of XMRV panels, updates of research efforts on test/panel development and other studies.
    Finally, FDA will periodically update the committee on progress in our understanding of XMRV and transfusion safety. As additional data are obtained on prevalence in blood donors and any associated transfusion risks, BPAC may be asked to advise FDA on appropriate measures to maintain the safety and availability of the blood supply.
    References:
    Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006;2:e25.
    Dong B, Kim S, Hong S, Das Gupta J, Malathi K, Klein EA, Ganem D, Derisi JL, Chow SA, Silverman RH. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A. 2007;104:1655-60.
    Schlaberg, R., Choe, D.J., Brown, K.R., Thaker, H.M., Singh, I.R. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high grade tumors. PNAS, 2009, 106(38):16351-6
    Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009;326:585-589.
    Qui X, P Swanson, Luk K-C, Das Gupta J, Onlamoon N, Silverman R, Villanger F, Devare S, Schochetman G, Hackett, J Jr. . XMRV: examination of viral kinetics, tissue tropism, and serological markers of infection. The 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010). At http://www.retroconference.org/2010/Abstracts/39393.htm. Accessed 3 March 2010.
    Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, Schlomm T. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol. 2008;43:277-83.
    DArcy, F., Foley, R., Perry, A., Marignol, L., Lawler, M., Gaffney, E., Watson, RGW, Fitzpatrick, J.M., and Lynch, T.H., No evidence of XMRV in Irish prostate cancer patients with R462Q mutation, European Urology Supplements, Vol. 7, Issue 3, p271, 2008
    Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, Miller K, Kurth R, Bannert N. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology. 2009;6:92.
    van Kuppeveld F J M, de Jong AS, Lanke KH, Verhaegh GW, Melchers WJG, Swanink CMA, Bleijenberg G, Netea MG, Galama JMD, van der Meer JWM. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 340, c1018 (2010)
    Groom HCT, Boucherit VC, Makinson K, Randal E, Baptista S, Hagan S, Gow GW, Mattes FM, Breuer J, Kerr JR, Stoye JP, Bishop KN. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology. 2010, 7:10 doi:10.1186/1742-4690-7-10.
    Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS ONE. 2010, 5 (1):e8519.
    Furuta, RA, Miyazawa T., Sugiyama, T., Kimura, T, Hirayama, F et al. The prevalence of Xenotropic Murine Leukemia Virus-related virus in Healthy Blood Donors in Japan. Presented at the Cold Spring Harbor Retrovirus Symposium. 18-23 May 2009
    Switzer W, Jia H, Hohn O, Zheng H, Tang S, Shankar A, Bannert N, Simmons G, Hendry M, Falkenberg VR, Reeves WC, Heneine W. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology. 2010; in press. http://www.retrovirology.com/content/7/1/57
    Fischer N, Schulz C, Stieler K, Hohn O, Lange C, Drosten C, Aepfelbacher M. Xenotropic murine leukemia virus-related gammaretrovirus in respiratory tract. Emerg Infect Dis. 2010; DOI: 10.3201/eid 1606.100066

    Appendix I: TABLE DOES NOT COME ACROSS ON THIS FORUM, SEE WEBSITE:
    Table. Updates of Prevalence Studies on XMRV Infection in Human Diseases and General Populations
    ------------------------------------------------------------------------------------------------------
    http://www.fda.gov/AdvisoryCommitte.../BloodProductsAdvisoryCommittee/ucm205013.htm

    contacts: ocod@fda.hhs.gov, shelly.burgess@fda.hhs.gov, michelle.yeboah@fda.hhs.gov
    2010 Meeting Materials, Blood Products Advisory Committee
    -
    July 26-27, 2010 Meeting of the Blood Products Advisory Committee
    Persons with disabilities having problems accessing any of these files may call 301-827-1277 for assistance.
    July 26-27, 2010: Meeting of the Blood Products Advisory Committee Announcement
    July 26-27, 2010: Blood Products Advisory Committee Meeting Waivers for Conflicts of Interest
    July 26-27, 2010: Blood Products Advisory Committee Draft Agenda (PDF - 22KB)
    July 26-27, 2010: Blood Products Advisory Committee - Topic 1 Final Babesia Issue Summary (PDF - 867KB)
    July 26-27, 2010: Blood Products Advisory Committee - Topic 2 Hemoglobin and Iron Issue Summary (PDF - 252KB)
    July 26-27, 2010: Blood Products Advisory Committee Meeting - Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Informational Presentation -
    -
    April 12, 2010 Meeting of the Blood Products Advisory Committee
    April 12, 2010: Blood Products Advisory Committee Meeting Agenda
    April 12, 2010: Blood Products Advisory Committee Meeting Member Roster (PDF - 46KB)
    April 12, 2010: Blood Products Advisory Committee Meeting Announcement
    Waivers for Conflicts of Interest for the April 12, 2010 Blood Products Advisory Committee Meeting

    Blood, Vaccines and Other Biologics
    -
    Advisory Committee Information Line: 1-800-741-8138 or 301-443-0572. Enter the 10 digit committee code for information about a specific Committee.
    Allergenic Products Advisory Committee
    Code number: 3014512388

    Blood Products Advisory Committee
    Code number: 3014519516


    Cellular, Tissue, and Gene Therapies Advisory Committee
    Code number: 3014512389

    Vaccines and Related Biological Products Advisory Committee
    Code number: 3014512391
     
  2. jspotila

    jspotila Senior Member

    Messages:
    1,098
    Likes:
    780
    This meeting is open to the public. I think the XMRV presentation was today. The meeting is not being webcast for free. FDAlive.com was offering a webcast or dvd for $100+. I don't know if a transcript will be made available for free, although I hope so. I believe Dr. Mikovits was attending today; Ms. Kim McCleary from the CFIDS Association was attending today.
     
  3. jackie

    jackie Senior Member

    Messages:
    591
    Likes:
    21
    the info i was sent, it that NORMALLY the cost of the webcast is $140......but that todays meeting is NOT being webcast live. No word yet on whether tomorrows meeting will be webcast. (my info came from xmrv gobal action) peresonally...id like to know why (i mean, why NOT?)
    j
     
  4. muffin

    muffin Senior Member

    Messages:
    940
    Likes:
    10
    A transcript will be available in the next few weeks. DID ANYONE GO?

    "This meeting is open to the public and press. It is not provided over the internet. A transcript will be available in the next few weeks."
    Shelly L. Burgess
    Public Affairs Specialist
    Food and Drug Administration
    Office of Public Affairs
    Office: 301.796.4651
    BB: 202.834.2939
    Email: shelly.burgess@fda.hhs.gov
    --------------------------------------------------------------------------------
    From: Muffin
    To: Burgess, Shelly
    Subject: July 26-27, 2010: Blood Products Advisory Committee Meeting XMRV --
    Is this meeting open to the public and press? Will this meeting be provided over the Internet in some form - either via a video feed or transcript? Thank you -

    July 26-27, 2010: Blood Products Advisory Committee Meeting - Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Informational Presentation
    BLOOD PRODUCTS ADVISORY COMMITTEE MEETING
    98 th Meeting, July 26-27, 2010
    Hilton Washington D.C./North
    620 Perry Parkway, Gaithersburg, MD
     
  5. jspotila

    jspotila Senior Member

    Messages:
    1,098
    Likes:
    780
    From CFIDS Association

    Posted on the Association's Facebook page this afternoon:

    Regarding the webcast (or lack therof), I emailed the Designated Federal Officer for this advisory committee and pointed out that the CFSAC meetings are webcast free in real time. I have no idea why FDA does not provide the same. Hopefully we will get a meeting summary soon, and not have to wait several weeks for the transcript.
     
  6. V99

    V99

    Messages:
    1,471
    Likes:
    5
    UK
    You forgot Dr Mikovits
     
  7. Frickly

    Frickly Senior Member

    Messages:
    1,046
    Likes:
    39
    Texas
    Where is the Wpi in this meeting?
     
  8. leelaplay

    leelaplay member

    Messages:
    1,546
    Likes:
    148
    I notice that this note names 6 groups. Is WPI the 7th?
     
  9. Rafael

    Rafael XMRV+ Member

    Messages:
    66
    Likes:
    1
    Ontario, Canada
    a detailed agenda (sorry if posted elsewhere) is at
    http://www.fda.gov/downloads/Adviso.../BloodProductsAdvisoryCommittee/UCM218990.pdf

    Monday's (Yesterday) agenda (just before public questions & lunch) included:

    9:45 a.m.
    Opening Remarks, Blaine Hollinger, M.D., Chair Statement of Conflicts of Interest, Announcements Committee Updates
    - Update from the HHS Advisory Committee Blood Safety and Availability and Summary of June 10- 11, 2010 meeting, Jerry Holmberg, Ph.D., Executive Secretary, Advisory Committee on Blood Safety and Availability (15’)
    - Summary of “Emerging Arboviruses: Evaluating the Threat to Transfusion and Transplantation Safety,” Workshop December 14-15, 2009, Deborah Taylor, Ph.D. (15’)
    - Summary of “Emerging Infectious Diseases: Evaluation to Implementation for Transfusion and Transplantation Safety” Workshop May 11-12, 2010, Paul Mied, Ph.D. and Melissa Greenwald, M.D. (30’)
    - Update on Q Fever Epidemic in the Netherlands, Hira Nakhasi, Ph.D., DETTD, OBRR, FDA (15’) Break
    Informational Presentations: Xenotropic Murine Leukemia Virus–Related Virus (XMRV)
    A. Introduction and Background, Indira Hewlett, Ph.D., DETTD, OBRR, FDA (10’)
    B. Identification of the New Human Retrovirus XMRV, Robert Silverman, Ph.D., The Cleveland Clinic Foundation (20’)
    C. Health Canada’s Perspective on XMRV, Peter Ganz, Ph.D., Health Canada (15’)
    D. An Update on CDC XMRV Activities, R. Michael Hendry, D.Sc., CDC (10’)
    E. An Update on FDA/OBRR XMRV Activities, Indira Hewlett, Ph.D., DETTD, OBRR, FDA (10’)
    F. An Update on Blood XMRV Working Group Studies, Graham Simmons, Ph.D., Blood Systems Research Institute (20’)
    i. Validation Panel Testing and ii. Donor Studies
    G. An Update on NCI XMRV Assay Development, Stuart Le Grice, Ph.D., National Cancer Institute (15’)

    Looking forward to hearing about all this (hopefully)
     
  10. Rafael

    Rafael XMRV+ Member

    Messages:
    66
    Likes:
    1
    Ontario, Canada
  11. Wasbeer

    Wasbeer

    Messages:
    78
    Likes:
    0
    Amersfoort, Netherlands
  12. Frickly

    Frickly Senior Member

    Messages:
    1,046
    Likes:
    39
    Texas
    From the CFIDS Association

    This was posted on facebook from the CFIDS Association: http://www.facebook.com/CFIDSAssn?ref=search

    "Dr. Mikovits responded to a question about testing multiply transfused individuals and she expressed concern about the CDC study but she did not make a formal presentation, although time was available during the public comment session."

    What are they saying? That it was Mikovits decision to not give a presentation? That if she wanted to talk she should have used time in the public comment session? VERY IRRITATING!
     
  13. Frickly

    Frickly Senior Member

    Messages:
    1,046
    Likes:
    39
    Texas
    This is from Heidi's comment on XMRV Global Action as she did attend the meeting:

    "Dr. Mikovits said the samples were tested from 1984 multiple times before and after transfusion on a patient who is XMRV+. Dr. Peterson had addressed this same issue in October 2009 CFSAC meeting in order to explain the need to protect the ...blood supply. Dr. Mikovits also addressed the 20 positive blood samples given to the CDC. They are trying to cry contamination of those samples. Her statement made clear that there was no possibility of contamination.

    She was NOT invited to speak. She was sent by the WPI to be a presence and to make comments to the committee if necessary. Many people were very, very glad to see here there."
    http://www.facebook.com/pages/XMRV-Global-Action/216740433250?ref=nf
     
  14. CBS

    CBS Senior Member

    Messages:
    1,502
    Likes:
    847

See more popular forum discussions.

Share This Page